Pfizer Plans To Give Diversified Businesses Time To Grow
This article was originally published in The Tan Sheet
Executive Summary
Pfizer plans to give its consumer products businesses "the opportunity to grow" as it integrates Wyeth into its operations, according to CEO Jeffrey Kindler
You may also be interested in...
Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
Rhinocort Aqua could be a first-in-class U.S. switch for the nasal corticosteroids, often cited as a potential class for switches. Pfizer gains right of first refusal for the product’s OTC rights from AstraZeneca.
Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
Rhinocort Aqua could be a first-in-class U.S. switch for the nasal corticosteroids, often cited as a potential class for switches. Pfizer gains right of first refusal for the product’s OTC rights from AstraZeneca.
Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
Rhinocort Aqua could be a first-in-class U.S. switch for the nasal corticosteroids, often cited as a potential class for switches. Pfizer gains right of first refusal for the product’s OTC rights from AstraZeneca.